Retention in a public healthcare system with free access to treatment: A Danish nationwide HIV cohort study

AIDS

Volumn 26, Issue 6, 2012, Pages 741-748

  Helleberg, Marie ^a,f   Engsig, Frederik N ^a   Kronborg, Gitte ^b   Larsen, Carsten S ^c   Pedersen, Gitte ^d   Pedersen, Court ^e   Gerstoft, Jan ^a   Obel, Niels ^a  

^a University of Copenhagen   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

continuity of patient care; HIV; lost to follow up; mortality; retention

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DENMARK; FEMALE; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; DELIVERY OF HEALTH CARE; DENMARK; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; RISK FACTORS; STATE MEDICINE;

EID: 84859107011     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834fa15e     Document Type: Article

References (31)

1. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons ofcauses of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
2. Ulett KB, Willig JH, Lin HY, Routman JS, Abroms S, Allison J, et al. The therapeutic implications oftimely linkage and early retention in HIV care. AIDS Patient Care STDS 2009; 23:41-49.
3. Sterne JA, May M, Costagliola D, de WF, Phillips AN, Harris R, et al. Timing ofinitiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
4. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption ofantiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
5. Daniel N, Schneider V, Pialoux G, Krivine A, Grabar S, Nguyen TH, et al. Emergence ofHIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients. AIDS 2003; 17:2126-2129. (Pubitemid 37297164)
6. Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost SD, Petropoulos CJ, et al. Selection ofdrug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-899. (Pubitemid 34409013)
7. Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual- and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis 2011; 52 (Suppl 2):S205-S207.
8. Metsch LR, Pereyra M, Messinger S, Del RC, Strathdee SA, Anderson-Mahoney P, et al. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis 2008; 47:577-584.
9. Centers for Disease Control and Prevention. Incorporating HIV prevention into the medical care of persons living with HIV. MMWR Recomm Rep 2003. pp. 1-24.
10. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sorensen HT. Cohort profile: the Danish HIV cohort study. Int J Epidemiol 2009; 38:1202-1206.
11. The Central Office of Civil Registration. The Civil Registration System in Denmark. Available from: http://www.cpr.dk/cpr/site.aspx?p=34.
12. The National Board of Health. The National Patient Registry. Available from: http://www.sst.dk/Informatik-og-sundhedsdata/Registre-og- sundhedsstatistik/Beskrivelse-af-registre/Landspatientregister. aspx?lang=en2007.
13. Marubini E VMG. Analyzing survival data from clinical trials and observational studies. John Wiley & Sons; 1995. pp. 331-363.
14. Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ. High rate ofloss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort. J Int AIDS Soc 2010; 13:29.
15. Lanoy E, Lewden C, Lievre L, Tattevin P, Boileau J, Aouba A, et al. How does loss tofollow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalite 2000 survey and death certificates. HIV Med 2009; 10:236-245.
16. Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, et al. Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol 2010; 63:1101-1109.
17. Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access toengagement: measuring retention in outpatient HIV clinical care. AIDS Patient Care STDS 2010; 24:607-613.
18. Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials 2002; 3:52-57. (Pubitemid 34183096)
19. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006; 59:829-835.
20. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, et al. Loss tofollow-up in an international, multicentre observational study. HIV Med 2008; 9:261-269. (Pubitemid 351517272)
21. Schepens T, Morreel S, Florence E, Koole O, Colebunders R. Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS 2010; 21:765-769.
22. Torian LV, Wiewel EW. Continuity ofHIV-related medical care, New York City, 2005-2009: do patients who initiate care stay in care? AIDS Patient Care STDS 2011; 25:79-88.
23. Gardner EM, McLees MP, Steiner JF, Del RC, Burman WJ. The spectrum ofengagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011; 52:793-800.
24. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB. The incidence rate ofHIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 2009; 14:995-1000.
25. Lohse N, Obel N, Kronborg G, Jorgensen LB, Pedersen C, Larsen CS, et al. Declining prevalence ofHIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004. Antivir Ther 2006; 11:591-600. (Pubitemid 44277424)
26. Audelin AM, Gerstoft J, Obel N, Mathiesen L, Laursen A, Pedersen C, et al. Molecular phylogenetics oftransmitted drug resistance in newly diagnosed HIV type 1 individuals in Denmark, a nation-wide study. AIDS Res Hum Retroviruses 2011; 27:1283-1290.
27. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival ofpersons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. (Pubitemid 351640011)
28. Lohse N, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Comorbidity acquired before HIV diagnosis and mortality in HIV-infected and uninfected persons: a Danish population-based cohort study. J Acquir Immune Defic Syndr 2011; 57:334-339.
29. Causes ofdeath in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
30. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: achallenge to survival with HIV infection. Clin Infect Dis 2007; 44:1493-1499. (Pubitemid 46801595)
31. Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, Cochonat K, et al. Characteristics ofand outcomes in HIV-infected patients who return to care after loss to follow-up. AIDS 2009; 23:1786-1789.